3680-69-1Relevant articles and documents
Synthesis and biological evaluation of some new tricyclic pyrrolo[3,2-e]tetrazolo[1,5-c]pyrimidine derivatives as potential antitubercular agents
Patil, Yogesh,Shingare, Ramesh,Choudhari, Amit,Borkute, Rachana,Sarkar, Dhiman,Madje, Balaji R.
, (2018)
A series of new tricyclic pyrrolo[3,2-e]tetrazolo[1,5-c]pyrimidines 8a–l were synthesized and characterized by IR, NMR (1H and 13C), and mass spectral analysis. The newly synthesized compounds 8a–l were inspected for their in vitro antitubercular activity against Mycobacterium tuberculosis (MTB) H37Ra using an established XTT reduction menadione assay (XRMA). The title compounds exhibited minimum inhibitory concentrations (MIC90) ranging from 0.09 to >30 μg/mL. Five compounds (8c, 8i–l) were further confirmed for their dose-dependent effect against MTB. These compounds were evaluated in the THP-1 infection model, where 8i (MIC90 = 0.35 μg/mL), 8j (MIC90 = 1.17 μg/mL), 8k (MIC90 = 2.38 μg/mL), and 8l (MIC90 = 1.17 μg/mL) demonstrated significant antitubercular activity. All the ex vivo active compounds showed insignificant cytotoxicity against the human cancer cell lines, HeLa, MCF-7, and THP-1. Inactivity of all these compounds against Gram positive and Gram negative bacteria indicates their specificity. Molecular docking studies in the active site of the sterol 14alpha-demethylase (CYP51) enzyme revealed a similar binding mode to the native ligand in the crystal structure, thereby helping to understand the ligand–protein interactions and to establish a structural basis for inhibition of MTB. The results suggest novel pharmacophores as selective and specific inhibitors against MTB that can be explored further to synthesize lead compounds against tuberculosis. In summary, the results clearly indicate the identification of some novel, selective, and specific inhibitors against MTB that can be explored further for potential antitubercular drugs.
Production system of medical intermediate 4-chloropyrrolopyrimidine
-
Paragraph 0019; 0021-0025; 0029-0040, (2020/03/06)
The invention discloses a production system of medical intermediate 4-chloropyrrolopyrimidine. The production system is used for a novel production process of 4-chloropyrrolopyrimidine by taking pyrrolo[2,3-d]pyrimidin-4-ol as a reaction substrate, and comprises a high-temperature and high-pressure stirring reaction kettle for preparing 4-chloropyrrolopyrimidine by taking pyrrolo[2,3-d]pyrimidin-4-ol as a substrate; the top of the high-temperature and high-pressure stirring reaction kettle is connected with an alkali liquor pool for absorbing tail gas through a pipeline with a valve; the bottom of the high-temperature and high-pressure stirring reaction kettle is connected with a distillation tower used for evaporating a solvent through a pipeline; the distillation tower is connected witha condenser used for condensing solvent steam and a washing kettle used for washing an obtained product; the condenser is connected with a solvent recovery tank used for recovering the solvent; and the washing kettle is connected with a suction filtration barrel used for separating a solid product. Because a large amount of POCl3 does not need to be used in a new production method, the quenching process is safe, the whole set of device is closed, little toxic gas is discharged, and the purpose of green production can be achieved.
Method for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine by adopting non-phosphorus chlorination reagent
-
Paragraph 0062-0071, (2020/08/25)
The invention discloses a method for preparing 4-chloro-7H-pyrrolo[2,3-d]pyrimidine from a non-phosphorus chlorination reagent, which is technically characterized by comprising the following steps: 1)preparing a Vilsmeier reagent from a non-phosphorus reagent and N,N-dimethylformamide (DMF) in an aprotic solvent; and 2) adding 4-hydroxy-7H-pyrrolo[2,3-d]pyrimidine into the prepared Vilsmeier reagent, and carrying out a chlorination reaction to generate the 4-chloro-7H-pyrrolo[2,3-d]pyrimidine. The objective of the invention is to provide the method for preparing the 4-chloro-7H-pyrrolo[2,3-d]pyrimidine by using the non-phosphorus chlorination reagent. A large amount of phosphorus-containing waste liquid in the production process can be avoided.